Sion Medical Ltd
Limor Bar serves as the Chief Innovations Technology Officer and Vice President of Customer Relations at Sion Medical Ltd since January 2016, focusing on advancing healthcare through innovation worldwide. Previously, Limor held roles such as Medical Division Manager at Bristol-Myers Squibb from October 2013 to January 2016, and Product Specialist at Gamida Ltd. from 2009 to January 2013. Earlier experience includes positions as Product Manager for Cardiovascular and Surgery at Luxembourg Institute of Health from 2006 to 2009, Product Specialist at Boston Scientific from 2003 to 2006, and Sales Representative. Limor Bar's academic credentials include a Doctor of Philosophy in Bioengineering and Biomedical Engineering from Tel Aviv University, alongside multiple degrees in Bioengineering and Biomedical Engineering from Ben-Gurion University of the Negev.
This person is not in any teams
Sion Medical Ltd
Sion Medical Ltd. is a leading manufacturer of single-use skin cleansing and dermatologic treatment, advanced wound care, burns remedy and surgical solutions for the professional healthcare sector. Sion Medical Ltd. currently operates through 6 locations worldwide, 5 state-of-the-art production facilities, as well as two sales and logistic companies in Europe and in North America. The company has 4 decades of experience in the production of Medical Devices and OTC Drugs. Sion Medical Ltd. is on the front line of Advance Wound Care Management and Infection Prevention with a vast array of specialized products. The Sion Medical Group aim is to develop new innovative products that will influence, support and improve the quality of healthcare through the practice and management of infection control, wound management as well and the application of epidemiology in the healthcare settings. The Company's Quality System is accredited to ISO 9001:2015, EN ISO 13485:2016, and in compliance with CFR Title 21 Parts 210, 211, 820. Our products are registered in the EU with CE certification and in the US under the FDA.